● Recruiting

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

Condition: Rheumatoid Arthritis (RA · Sponsor: Cullinan Therapeutics Inc.

PhasePhase 1

Planned participants37

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.

This description comes directly from the study's public registry record.

Talk to the study team

Amy Gubits, MPH · +1 617 410 4650 · ClinOps@cullinantx.com

Always discuss trial participation with your own doctor first.

Locations (3)

University Hospital Erlangen	Erlangen, Germany	Recruiting
University Hospital Heidelberg	Heidelberg, Germany	Recruiting
Fondazione Policlinico Universitario A Gemelli	Rome, Italy	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06994143